QUESTION: Does a heterobivalent molecule that recognizes both FAP and SSTR2 demonstrate improved efficacy in tumor-targeting and in vivo pharmacokinetics compared with those of its corresponding monomers? The gene discussed is FAP; the disease is neoplasm.